Kelsey Goodwin
Stock Analyst at Guggenheim
(0.29)
# 2564
Out of 5,331 analysts
18
Total ratings
41.67%
Success rate
-7.16%
Average return
Main Sectors:
Top Industries:
Name | Action | PT | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
URGN UroGen Pharma | Reiterates: Buy | n/a | n/a | n/a | 2 | Apr 29, 2025 | |
IPSC Century Therapeutics | Reiterates: Buy | n/a | n/a | n/a | 3 | Mar 28, 2025 | |
GNLX Genelux | Initiates Coverage On: Buy | 8 | 2.6 | 207.69% | 1 | Oct 29, 2024 | |
NUVL Nuvalent | Maintains: Strong Buy | 99 105 | 77.59 | 35.33% | 2 | Sep 16, 2024 | |
MGNX Macrogenics | Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 31, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Sep 13, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | n/a | n/a | n/a | 3 | Jun 20, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Oct 31, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Oct 31, 2022 |